Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?

Drugs
W J Remme

Abstract

In addition to being accepted therapy in hypertension and heart failure, ACE inhibitors may well offer a new dimension in anti-ischaemic therapy. Currently, anti-ischaemic properties have been demonstrated by ACE inhibitors in selected patient groups, including patients with left ventricular dysfunction with or without a direct temporal relationship with myocardial infarction. Anti-ischaemic effects of ACE inhibitors become apparent late after initiation of treatment and suggest a structural rather than a functional effect. Underlying mechanisms may include a reduction in ventricular dilatation and (abnormal) cardiac hypertrophy, leading to less myocardial oxygen demand and, possibly, improved subendocardial blood supply, and vasculoprotective effects, i.e. anti-atherosclerotic and antiremodelling properties, a beneficial effect on the fibrinolytic system and an improvement in abnormal endothelial vasodilator function. The latter aspect is most probably the pivotal mode of action where the anti-ischaemic profile of ACE inhibition is concerned. An improvement in endothelial dysfunction has been shown in patients with mild to moderate coronary artery disease [Trial on Reversing ENdothelial Dysfunction (TREND)]. It is of importanc...Continue Reading

Citations

Dec 21, 2000·Current Atherosclerosis Reports·N Sharma, T C Andrews
Nov 5, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·K K Veeravalli, A Akula
Jan 13, 2001·The Annals of Thoracic Surgery·J FengE R Rosenkranz
Jun 13, 2001·Journal of the American College of Cardiology·M E KhalilI A Alhaddad
Oct 7, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·K K VeeravalliM K Kota
Jul 9, 2002·Clinical and Experimental Pharmacology & Physiology·Henry H HolzgrefeJames R Powell
Aug 7, 2002·The Journal of Clinical Investigation·Joost P SchanstraJean-Loup Bascands
Jun 4, 1999·Journal of Clinical Pharmacology·M M McConnaugheyA J Ingenito
May 21, 2005·The American Journal of Cardiology·Bernard R ChaitmanJohn H Lawrence
Apr 20, 2005·International Journal of Cardiology·Dimitris TousoulisChristodoulos Stefanadis
May 2, 2001·The American Journal of Medicine·R TabibiazarS G Rockson
Feb 24, 2012·International Journal of Cardiology·Alison L MüllerNaranjan S Dhalla
Jan 27, 2015·Cell Biochemistry and Biophysics·Ou YangJian Kong
Jan 13, 2015·Vascular Pharmacology·Domenico Regoli, Fernand Gobeil
Apr 13, 2005·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yasuyuki TanakaSeibu Mochizuki
Sep 24, 2021·Acta Physiologica·Philipp HillmeisterIvo Buschmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

Arrhythmogenic Right Ventricular Dysplasia

Arrhythmogenic right ventricular dysplasia is a congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the right ventricle wall and loss of myocardial cells. Primary injuries usually are at the free wall of the right ventricular and right atria resulting in ventricular and supraventricular arrhythmias. Discover the latest research on arrhythmogenic right ventricular dysplasia here.